Table 1.
Patient baseline characteristics.
| Subtype | ||||||
|---|---|---|---|---|---|---|
| Covariate | LEVEL | UPS N = 25 |
LMS N = 20 |
Other N = 43 |
Total N = 88 |
|
| Site | University of Iowa | 4 (16.0) | 3 (15.0) | 8 (18.6) | 15 (17.0) | |
| Mayo Clinic | 6 (24.0) | 1 (5.0) | 5 (11.6) | 12 (13.6) | ||
| University of Minnesota | 10 (40.0) | 2 (10.0) | 9 (20.9) | 21 (23.9) | ||
| Wash U, St. Louis | 5 (20.0) | 14 (70.0) | 21 (48.8) | 40 (45.5) | ||
| Gender | Female | 7 (28.0) | 14 (70.0) | 18 (41.9) | 39 (44.3) | |
| Male | 18 (72.0) | 6 (30.0) | 25 (58.1) | 49 (55.7) | ||
| Race | Asian | 1 (4.0) | 0 (0) | 0 (0) | 1 (1.1) | |
| Black/African-American | 1 (4.0) | 4 (20.0) | 4 (9.3) | 9 (10.2) | ||
| Hispanic or Latino | 1 (4.0) | 0 (0) | 0 (0) | 1 (1.1) | ||
| White | 22 (88.0) | 16 (80.0) | 39 (90.7) | 77 (87.5) | ||
| Extremity/trunk | 20 (80.0) | 6 (30.0) | 26 (60.5) | 52 (59.1) | ||
| Primary Tumor Location | Retroperitoneal | 1 (4.0) | 1 (5.0) | 5 (11.6) | 7 (8.0) | |
| Head and neck | 1 (4.0) | 0 (0) | 3 (7.0) | 4 (4.5) | ||
| Abdominal/pelvic | 3 (12.0) | 13 (65.0) | 9 (20.9) | 25 (28.4) | ||
| No | 6 (24.0) | 1 (5.0) | 7 (16.3) | 14 (15.9) | ||
| Prior treatment | Yes | 19 (76.0) | 19 (95.0) | 36 (83.7) | 74 (84.1) | |
| Gemcitabine-based | 7 | 15 | 12 | 34 | ||
| Prior treatment | Anthracycline-based | 17 | 12 | 20 | 49 | |
| TKI-based | 6 | 8 | 13 | 27 | ||
| Investigational drug | 4 | 12 | 8 | 24 | ||
| Trabectedin | 2 | 12 | 2 | 16 | ||
| 4+ | 12 (50.0) | 9 (45.0) | 21 (48.8) | 42 (48.3) | ||
| Neutrophil/lymphocyte ratio | <4 | 12 (50.0) | 11 (55.0) | 22 (51.2) | 45 (51.7) | |
| Missing | 1 | 0 | 0 | 1 | ||
| Locally Advanced | 1 (4.0) | 0 (0) | 7 (16.3) | 8 (9.1) | ||
| Tumor status when starting therapy | Metastatic | 24 (96.0) | 20 (100) | 36 (83.7) | 80 (90.9) | |
| 0 | 9 (36.0) | 10 (50.0) | 23 (53.5) | 42 (47.7) | ||
| ECOG score | 1 | 13 (52.0) | 8 (40.0) | 15 (34.9) | 36 (40.9) | |
| 2 | 3 (12.0) | 2 (10.0) | 5 (11.6) | 10 (11.4) | ||
| Ipilimumab | 0 (0) | 0 (0) | 1 (2.3) | 1 (1.1) | ||
| Immunotherapy treatment | Nivolumab | 0 (0) | 1 (5.0) | 5 (11.6) | 6 (6.8) | |
| Pembrolizumab | 21 (84.0) | 5 (25.0) | 21 (48.8) | 47 (53.4) | ||
| Ipilimumab with Nivolumab | 2 (8.0) | 12 (60.0) | 13 (30.2) | 27 (30.7) | ||
| Other | 2 (8.0) | 2 (10.0) | 3 (7.0) | 7 (8.0) | ||
| No | 17 (89.5) | 16 (84.2) | 36 (94.7) | 69 (90.8) | ||
| Clinical Trial | Yes | 2 (10.5) | 3 (15.8) | 2 (5.3) | 7 (9.2) | |
| Missing | 6 | 1 | 5 | 12 | ||
| No | 19 (76.0) | 17 (85.0) | 36 (83.7) | 72 (81.8) | ||
| Concurrent radiation | Yes | 6 (24.0) | 3 (15.0) | 7 (16.3) | 16 (18.2) | |
| No | 24 (96.0) | 19 (95.0) | 40 (93.0) | 83 (94.3) | ||
| Concurrent chemotherapy | Yes | 1 (4.0) | 1 (5.0) | 3 (7.0) | 5 (5.7) | |
| Complete Response (CR) | 1 (4.0) | 0 (0) | 0 (0) | 1 (1.1) | ||
| Best overall radiographic response | Partial Response (PR) | 7 (28.0) | 9 (45.0) | 4 (9.3) | 20 (22.7) | |
| Stable Disease (SD) | 7 (28.0) | 3 (15.0) | 18 (41.9) | 28 (31.8) | ||
| Progressive Disease (PD) | 10 (40.0) | 8 (40.0) | 21 (48.8) | 39 (44.3) | ||
| No | 10 (40.0) | 6 (30.0) | 18 (41.9) | 34 (38.6) | ||
| Immunotherapy stopped | Yes | 15 (60.0) | 14 (70.0) | 25 (58.1) | 54 (61.4) | |
| Progression | 12 (80.0) | 10 (71.4) | 17 (68.0) | 39 (72.2) | ||
| Reason for stopping immunotherapy | Toxicity | 2 (13.3) | 2 (14.3) | 5 (20.0) | 9 (16.7) | |
| Other | 1 (6.7) | 2 (14.3) | 3 (12.0) | 6 (11.1) | ||
| No | 13 (68.4) | 12 (63.2) | 30 (78.9) | 55 (72.4) | ||
| Immune-mediated adverse event | Yes | 6 (31.6) | 7 (36.8) | 8 (21.1) | 21 (27.6) | |
| Missing | 6 | 1 | 5 | 12 | ||
| No | 3 (50.0) | 1 (14.3) | 0 (0) | 4 (19.0) | ||
| Intervention for adverse event | Yes | 3 (50.0) | 6 (85.7) | 8 (100) | 17 (81.0) | |
| No | 5 (20.0) | 5 (25.0) | 11 (25.6) | 21 (23.9) | ||
| Patient with progressive disease | Yes | 20 (80.0) | 15 (75.0) | 32 (74.4) | 67 (76.1) | |
| 25 | 20 | 43 | 88 | |||
| Age at therapy start | N | 60 | 64 | 54 | 59 | |
| Median | (31–82) | (34–81) | (21–80) | (21–82) | ||
| (Min-Max) | 24 | 20 | 43 | 87 | ||
| Most recent ANC a (cells/mm3) | N | 4040 | 3150 | 4100 | 4000 | |
| Median | (1600–33,720) | (230–9200) | (1330–28,470) | (230–33,720) | ||
| (Min-Max) | 24 | 20 | 43 | 87 | ||
| Most recent ALC b (cells/mm3) | N | 995 | 850 | 1000 | 1000 | |
| Median | (200–2600) | (160–2100) | (100–2650) | (100–2650) | ||
| (Min-Max) | 24 | 20 | 43 | 87 | ||
| N/L ratio | N | 4.0 | 3.4 | 3.5 | 3.8 | |
| Median | (0.9–32.4) | (0.3–18.0) | (0.7–80.0) | (0.3–80.0) | ||
| (Min-Max) | 19 | 19 | 36 | 74 | ||
| Number of prior lines of treatment 1 | N | 2 | 3 | 2 | 2 | |
| Median | (1–8) | (1–8) | (1–6) | (1–8) | ||
| (Min-Max) | 6 | 3 | 7 | 16 | ||
| Radiation dose (Gy) | N | 65 | 30 | 55 | 50 | |
| Median | (25–100) | (10–45) | (30–300) | (10–300) | ||
| (Min-Max) | 25 | 20 | 43 | 88 | ||
| Length of follow-up (months) | N | 11.3 | 12.3 | 10.6 | 11.1 | |
| Median | (1.2–24.2) | (0.9–31.3) | (0.1–31.7) | (0.1–31.7) | ||
| (Min-Max) | ||||||
a Absolute neutrophil count (ANC). b Absolute lymphocyte count (ALC). 1 Fourteen patients received first-line immunotherapy.